Charcot Leyden Crystals in Pathology

Clinical Significance of Charcot-Leyden Crystals in Bronchial and Sinonasal Pathological Samples

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03999242

Acronym

CLCpath

Enrollment

200

Registered

2019-06-26

Start date

2019-04-01

Completion date

2019-05-15

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

nasal polyposis, rhinosinusitis, Charcot Leyden Crystals, Eosinophils

Brief summary

Charcot Leyden crystals (CLC) are sometime reported in pathological reports of airway or sinonasal samples but their clinical significance remain elusive. The investigators organized a retrospective analysis of all consecutive patients with CLC seen at our institution between 1986 and 2019

Detailed description

In recent years, improved knowledge of eosinophilic inflammation has led to the approval of biologics aimed at inhibiting the pathways of eosinophilic activation, notably via the interleukin 5 pathway in eosinophilic asthmatic patients uncontrolled despite receiving maximum doses of standard drugs. These treatments showed efficacy in asthmatic patients with a high level of eosinophils in their induced sputum (\> 3%) and the criteria were extended to those with circulating eosinophilia (\> 300 / mm3). Eosinophils are therefore an important biomarker for phenotyping asthmatic patients. The Charcot-Leyden crystals are a reflection of the presence of eosinophils, and are sometimes found in some pathological samples. It is hypothesized that the presence of Charcot-Leyden crystals, a reflection of tissue eosinophilia, is a predictive factor for the efficacy of anti-IL5 biotherapies in patients with severe eosinophilic asthma.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Having Charcot Leyden Crystals in a pathological sample

Exclusion criteria

* Having Charcot Leyden Crystals in a pathological sample taken outside the airways the nose and the sinus

Design outcomes

Primary

Measure	Time frame
'Level of asthma control/severity according to GINA stepwise approach	Baseline (day 0)

Secondary

Measure	Time frame	Description
Cumulative annualized dose of inhaled and systemic corticosteroids	Baseline (day 0) to Month 12	The quantity of corticosteroids consumed during the course of a year.

Countries

France

Outcome results